Moazzam Habib, MD
Endocrinology, Diabetes & Metabolism · Indianapolis, INNPI 1639270721
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $19,230 of the $29,049 with a category attached, or 66.2%. 58 manufacturers reported payments, led by Lilly USA, LLC at 39.3% of the total. Reporting peaked in 2019 at $12,952 and has fallen 79.1% since, to $2,711 in 2025.
Across 1,217 payments — averaging $23.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$11K
- Novo Nordisk$2K
- Mannkind Corporation$2K
- Corcept Therapeutics$1K
- Amgen$1K
- AstraZeneca$1K
- plus $10K from 52 others
What the payments were for
- Consulting fees$3,25011%
- Speaking & faculty fees$5,40019%
- Travel & lodging$1,0904%
- Food & beverage$19,23066%
- Education$790%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$29,049 in reported general payments places this provider in the 85th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 150 | $189,668 |
| OzempicSemaglutide | 107 | $160,461 |
| KerendiaFinerenone | 134 | $117,617 |
| TrulicityDulaglutide | 80 | $106,256 |
| JardianceEmpagliflozin | 116 | $92,221 |
| RybelsusSemaglutide | 54 | $83,337 |
| Tresiba Flextouch U-200Insulin Degludec | 80 | $73,968 |
| FarxigaDapagliflozin Propanediol | 64 | $69,714 |
| Norditropin FlexproSomatropin | 17 | $69,028 |
| TradjentaLinagliptin | 73 | $55,659 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 56 | $41,531 |
| Tresiba Flextouch U-100Insulin Degludec | 66 | $32,864 |
| JanuviaSitagliptin Phosphate | 31 | $32,122 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 38 | $29,035 |
| Repatha SureclickEvolocumab | 33 | $28,425 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $11,423 | $306,102266 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp | $1,933 | $253,384172 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Trijardy Xr, Glyxambi | $259 | $196,256249 claims |
| BayerKerendia | $738 | $117,617134 claims |
| AstraZenecaFarxiga | $1,141 | $69,71464 claims |
| MerckJanuvia, Janumet Xr, Steglatro | $668 | $63,90163 claims |
| AbbVieSynthroid | $953 | $17,325213 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCCycloset | $92 | $12,78813 claims |
| PfizerGenotropin | $85 | $11,92213 claims |
| Clarus Therapeutics Inc.Jatenzo | $88 | $9,85111 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $141 | $7,16412 claims |
| Antares Pharma, Inc.Xyosted | $219 | $6,68411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
Other endocrinology, diabetes & metabolism in Indianapolis
- Ernest AsamoahIndianapolis$959K
- Hisham AllababidiIndianapolis$195K
- Michael EconsIndianapolis$74K
- Carmella Evans-MolinaIndianapolis$55K
- Manuel Bello SeguraIndianapolis$44K
- James EdmondsonIndianapolis$10K
- James ScheidlerIndianapolis$8K
- Cary MariashIndianapolis$6K
- Jayender ChintaparthiIndianapolis$5K
- Munro PeacockIndianapolis$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.